Skip to main
HRMY

HRMY Stock Forecast & Price Target

HRMY Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 38%
Sell 13%
Strong Sell 0%

Bulls say

Harmony Biosciences Hldgs is a commercial-stage pharmaceutical company with a promising outlook due to their sole source of revenue, Wakix, experiencing strong underlying demand and potential for franchise expansion in CNS indications. Positive legal decisions for Wakix patents and successful clinical development of clemizole hydrochloride in Dravet or Lennox-Gastaut syndromes could provide additional upside to their current outlook. Risks include potential competition in the sodium oxybate market, slower growth in patient adds, unsuccessful clinical trials, and competition from generic pitolisant. With limited cash reserves, the success of future growth drivers and pipeline assets will be crucial for sustaining positive cash flows.

Bears say

Harmony Biosciences Hldgs is facing potential risks, such as safety concerns and regulatory outcomes, that could negatively impact its future financial performance. Additionally, its pipeline drugs have longer half-lives than its competitors, potentially making it less attractive for daily dosing. Its focus on assets with revenue potential in the 2028-2032 timeline suggests a lack of near-term profitability, and its reliance on drug repurposing and potential recruitment difficulties highlight potential challenges in product development.

HRMY has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 38% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Harmony Biosciences Holdings (HRMY) Forecast

Analysts have given HRMY a Buy based on their latest research and market trends.

According to 8 analysts, HRMY has a Buy consensus rating as of Sep 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Harmony Biosciences Holdings (HRMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.